| Dec'19 | Dec'18 | Dec'17 | ||||
|---|---|---|---|---|---|---|
Revenue: | ||||||
Grant revenue | ||||||
2,361 | 668 | - | ||||
Operating expenses: | ||||||
Research and development | ||||||
30,911 | 15,455 | 6,210 | ||||
General and administrative | ||||||
11,186 | 4,857 | 2,328 | ||||
Total operating expenses | ||||||
42,097 | 20,312 | 8,538 | ||||
Loss from operations | ||||||
-39,736 | -19,644 | -8,538 | ||||
Other income (expense): | ||||||
Interest income | ||||||
1,582 | 387 | 52 | ||||
Interest expense | ||||||
1,076 | 3,924 | 2,723 | ||||
Foreign exchange gain | ||||||
-17 | 0 | - | ||||
Fair Value Adjustment of Warrants | ||||||
0 | -11 | -1,019 | ||||
Unrealized Gain (Loss) on Derivatives | ||||||
0 | -676 | -57 | ||||
Total other income (expense) | ||||||
489 | -4,202 | -1,709 | ||||
Net loss | ||||||
-39,247 | -23,846 | -10,247 | ||||
Net loss per common share, basic and diluted (in usd per share) | ||||||
-1.43 | -4.49 | -13.78 | ||||
Weighted average common shares outstanding, basic and diluted (in shares) | ||||||
27,493 | 5,305 | 743 | ||||
Grant revenue | ||||||
Total revenue | ||||||
1,786 | 668 | - | ||||
Revenue under collaborative agreement | ||||||
Total revenue | ||||||
575 | 0 | - | ||||